Advanced

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease : Dawn of a New Era

Barker, Roger A. LU ; Parmar, Malin LU ; Studer, Lorenz and Takahashi, Jun (2017) In Cell Stem Cell 21(5). p.569-573
Abstract

Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting. Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.

Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cell Stem Cell
volume
21
issue
5
pages
5 pages
publisher
Cell Press
external identifiers
  • scopus:85032947277
  • wos:000414251200006
ISSN
1934-5909
DOI
10.1016/j.stem.2017.09.014
language
English
LU publication?
yes
id
34ec549d-4bda-4697-8896-886201516c7f
date added to LUP
2017-11-16 08:28:15
date last changed
2018-02-25 04:20:36
@misc{34ec549d-4bda-4697-8896-886201516c7f,
  abstract     = {<p>Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting. Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.</p>},
  author       = {Barker, Roger A. and Parmar, Malin and Studer, Lorenz and Takahashi, Jun},
  issn         = {1934-5909},
  language     = {eng},
  month        = {11},
  number       = {5},
  pages        = {569--573},
  publisher    = {Cell Press},
  series       = {Cell Stem Cell},
  title        = {Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease : Dawn of a New Era},
  url          = {http://dx.doi.org/10.1016/j.stem.2017.09.014},
  volume       = {21},
  year         = {2017},
}